Targeted Serum Metabolomic Profiling and Machine Learning Approach in Alzheimer's Disease using the Alzheimer's Disease Diagnostics Clinical Study (ADDIA) Cohort

*Dany Mukesha[1,18], Maité Sarter[2], Mélitine Dubray[3], Floris Durand[3], Stéphanie Boutillier[4], Lucas D. Pham-Van[4], David Halter[3], Seval Kul[3], Frédéric Blanc[5], Hakan Gürvit[6], Tamer Demiralp[6], Bruno Dubois[7], Audrey Gabelle[8], Moira Marizzoni[9], Giovanni B. Frisoni[10], Florence Pasquier[11], François Sellal[12,19], Adrian Ivanoiu[13], Jean-Christophe Bier[14], Renaud David[15], Jean-François Démonet[16], Eloi Magnin[17], Guillaume Sacco[15,18], Hüseyin Firat[1,2,3,4]

[1] **Firalis SA**, 17 rue du fort, 68330 Huningue, France, [2] **Firalis Molecular Precision SA**, Huningue, France, [3] **Lodiag SAS**, Huningue, France, [4] **Amoneta Diagnostics SAS**, Huningue, France, [5] **Hôpitaux Universitaires de Strasbourg**, France, [6] **Istanbul University**, Istanbul, Turkey, [7] **Assistance Publique - Hôpitaux de Paris**, France, [8] **Centre Hospitalier Universitaire de Montpellier**, Université de Montpellier, Institut des Neurosciences, France, [9] **IRCCS Centro San Giovanni di Dio Fatebenefratelli**, Brescia, Italy, [10] **University Hospital of Geneva**, Switzerland, [11] **Centre Hospitalier Régional Universitaire de Lille**, France, [12] **Hôpitaux Civils de Colmar**, France, [13] **Cliniques Universitaires Saint-Luc**, Brussels, Belgium, [14] **Hôpital Erasme,** H.U.B., Université Libre de Bruxelles, Neurological Department, Belgium, [15] **Centre Hospitalier Universitaire de Nice**, France, [16] **Centre Hospitalier Universitaire Vaudois**, Lausanne, Switzerland, [17] **Centre Hospitalier Universitaire de Besançon**, France, [18] **Université Côte d'Azur**, INSERM, CNRS, IPMC, France, [19] **INSERM U-1329, Faculté de Médecine, Université de Strasbourg**, France and **CombiDiag** (Combinatorial Early-Stage Diagnosis for Alzheimer's, Horizon-MSCA – GA#101071485) and **ADDIA** (H2020 – GA#674474) consortia

* Corresponding authors: danymukesha@gmail.com, **Firalis S.A. 17 Rue du Fort, 68330 Huningue, France.**

Abstract

Background: Metabolic biomarkers can potentially be used for early diagnosis, prognostic

risk stratification and/or early treatment and prevention of individuals at risk to develop

Alzheimer's disease (AD).

Objective: Our goal is to evaluate changes in metabolite concentration levels associated with

AD to identify biomarkers that could support early and accurate diagnosis and therapeutic

interventions by using targeted mass spectrometry and machine learning approaches.

Methods: Serum samples collected from a total of 107 individuals, including 55 individuals

diagnosed with AD and 52 healthy controls (HC) enrolled previously to ADDIA cohort were

analyzed using the Biocrates® 400 metabolite panel. Several machine learning models

including Lasso, Random Forest, and XGBoost were trained to classify AD and HC.

Repeated cross-validation was used to ensure performance evaluation.

Results: We identified 18 metabolites with nominal differences (p<0.05; AUC>0.60)

between AD and HC. These included alterations in acylcarnitines, phosphatidylcholines,

sphingomyelins, triglycerides, and amino acids, suggesting disruptions in lipid metabolism,

mitochondrial function, and oxidative stress. The best model achieved an average AUC of

0.88 on the train set and 0.73 on the test set. Classification performance was further improved

by combining multiple metabolites in a single panel and adding *APOE* genotyping

(AUC=0.902).

*Conclusions***:** These results highlight important metabolic signatures that could help to

reduce misdiagnosis and support the development of metabolomic panels to detect AD. The

combination of multiple serum metabolic biomarkers and *APOE* genotyping can

significantly improve classification accuracy and potentially assist in making non-invasive,

cost-effective diagnostic approach.

Keywords: Alzheimer's Disease, Biomarkers, Metabolomics, Machine Learning, Mass

Spectrometry, Neurodegenerative Disorders, Precision Medicine, Serum.

Introduction

Alzheimer's disease (AD) is a progressive neurodegenerative disease and represents the most common cause of neurocognitive disorder worldwide [1]. AD is clinically manifested by a gradual decline in memory and cognitive function that becomes more pronounced as the disease progresses [2]. At the down of anti-amyloid immunotherapies and more than ever before, the early detection of AD is crucial for timely intervention and effective treatment of the disease. However, due to the heterogeneity of disease progression, early detection of AD remains difficult [3]. To date, most diagnostic methods are based on clinical assessment, neuroimaging and cerebrospinal fluid (CSF) analysis, which are either invasive or costly, limiting their routine use [4,5]. Blood based biomarkers have been recently developed with encouraging performances [6].

First introduced in 1998 [7], metabolomics is a rapidly evolving discipline providing additional insights into the study of biochemical processes and disease mechanisms. By profiling metabolites in body fluids such as blood, urine, or CSF, metabolic changes associated with diseases such as AD can be identified. The appeal of blood metabolomics lies in its minimal invasiveness and its potential for early detection of disease. The changes in metabolic profile can occur up to 25 years before the clinical symptoms of AD [8]. In the context of AD, metabolomics holds promise not only for diagnosis but also for improving clinical trials. The current low success rate in AD drug development is often due to late-stage interventions. Identifying reliable metabolomic biomarkers and understanding their changes could facilitate early diagnosis and allow preventive and therapeutic interventions to be delivered at a stage where they are more likely to be effective.

Given the need for a non-invasive, cost-effective and scalable approach, serum derived from peripheral blood was used for this study as it combines accessibility with a greater likelihood of finding pathophysiological biomarkers in AD [9,10]. Several studies have shown

that the use of metabolomics has already enabled the detection of subtle, disease-specific

patterns in serum that reflect underlying AD-related metabolic changes [11–13]. Although the

concentrations of blood biomarkers are lower due to the blood-brain barrier, recent advances

in metabolomic profiling enable the detection of significant disease-related metabolic

changes [13]. Furthermore, machine learning models, which are useful for dealing with

complex data sets, have shown great potential for improving the accuracy of blood

biomarker-based diagnostics [14–16].

The aim of this study was to identify serum biomarkers, particularly metabolites, detect

and differentiate AD from healthy control (HC) using an approach that integrates

metabolomic analysis and machine learning techniques.

Material and Method

Sampling and laboratory analysis

The serum samples from ADDIA cohort (NCT03030586) were analyzed using the

AbsoluteIDQ® p400 HR kit (Biocrates Life Sciences AG). The extraction was conducted

with a loading volume of 10 µL per sample and analyzed with LC-MS/MS and FIA-MS/MS.

The data underwent quality control, statistical analysis, and machine learning (Lasso,

Random Forest, Naïve Bayes, PLS, XGBoost) to identify metabolomic signatures for AD

classification (**Figure 1**).

1. Laboratory experiment

2. Statistical & Bioinformatics analysis

Figure 1. Targeted metabolomics workflow for identifying metabolic patterns in AD. Abbreviations:

AD: Alzheimer's disease; HC: Healthy controls; FIA-MS/MS: Flow injection analysis tandem mass

spectrometry; LC-MS/MS: Liquid Chromatography coupled to tandem Mass Spectrometry; QC:

Quality control.

Study participants and data retrieval

A total of 107 biological samples were collected, including 52 HC and 55 AD patients.

MetIDQ software, which is an integral part of the AbsoluteIDQ p400 kit from Biocrates Life

Science AG, was used for peak selection, identification, and quantitative assessment. The

concentrations of metabolites subjected to FIA-MS/MS were automatically calculated by the

software. The analyte peaks detected by LC-MS/MS were integrated with Thermo Xcalibur

software version 4.3. Concentrations [µmol/l] were determined from the calibration

standards using the appropriate quantification method provided in the kit. This approach

facilitated the retention of metabolites that exceeded the detection limit but fell below the

quantification limit, as specified by the Biocrates software. All retrieved data were loaded,

quality-assessed, data processing and fully analyzed using R and RStudio (programming

language GNU R, version 4.4.1; RStudio version 2024.9.0.375).

APOE genotyping

The *APOE* genotyping was performed for each sample using the CE-IVDR APOEasy®

kits, providing accurate determination of the 6 *APOE* genotypes [17]. Genotyping data were

included in the analysis to evaluate the combined influence of genetic and metabolic factors

on disease classification and biomarker identification.

Data preparation and quality control(QC)

Imputation for missing values

We imputed the values that were missing because they were below the Limit Of

Detection (LOD) using a *logspline* algorithm between the thresholds LOD and LOD/2 [18]. The

values that were missing at random because of technical problems were imputed differently.

We obtained comparable results while imputing them with a *kNN* (k-nearest neighbors)

approach [19] and the *MICE* (Multivariate Imputation by Chained Equations) approach [20,21].

This approach helped to maintain the integrity of the dataset by providing a consistent

method for dealing with missing values as they are below LOD. We examined the

proportions of missing data for different biomarkers and samples. Metabolites with more

than 20% missing values were excluded from further analysis.

Data pre-processing

The concentrations were normalized to biocrates quality control level 2 (QC2) samples,

as recommended by the manufacturer. For data transformation and scaling, we used $log10$

transformation for the analysis of covariance (ANOVA) and $log2$ transformation for

Principal component analysis (PCA). The data were scaled to unit variance before the PCA.

We did not scale the data for ANOVA and Two-sample T-Test. For batch and biological

effects corrections, linear regression model was used [22]. Technical batch effects were

originally minimized after normalizing all plates to Biocrates QC values. To account for

biological variability and residual batch effects, confounding factors such as age, sex, group,

and batch were included in the model.

Statistic analysis and modelling

We first performed descriptive statistics to show an overview of the patient metadata in

the dataset. These include the number of patients in each group as well as the sex and age

distribution, and the confounding factors that may need to be adjusted for in subsequent

analyses.

The unsupervised analysis was then conducted using PCA, to evaluate of strong patterns

and detect the potential outliers from the dataset.

Supervised analysis was performed using multivariate analysis of variance (ANOVA) to

evaluate the effects of age, sex, group and batch on biomarker levels. Where it was

applicable, the *post-hoc* tests were conducted to further explore the specific group

differences, and adjustments were made for multiple comparisons to control for the risk of

Type I errors. We then performed a statistical comparison between two groups using

Student's t-test and the adjusted *p-values* were calculated using the False Discovery Rate

correction method using the Benjamini-Hochberg procedure. The results of these tests were

visualized using volcano plots of *p-value* and *q-value* distributions. The fold change analyses

were performed to measure of the relative difference in means between the two groups, with

a log_2 transformation.

The Area Under the Receiver Operating Characteristic Curve (AUC or AUC-ROC) was

calculated for individual metabolite to evaluate their discriminatory power[23,24]. An AUC

score of 1 indicates a perfect classifier, while a score of 0.5 indicates no discriminatory power

(random guessing) [25]. For our AD classification, AUC helped determine how well the model

distinguishes AD patients from HC.

Identification of significant metabolites

Differential metabolite expressions between AD and HC were assessed. Metabolites

showing statistically significant differences (p-value<0.05) were selected for enrichment

analysis.

Metabolite Set Enrichment Analysis (MSEA)

To identify enriched metabolic pathways and determine their biological relevance in

AD, we performed an enrichment analysis on the significantly differentially expressed

metabolites between AD and HC. In order to provide insights into potential dysregulated

biochemical processes in AD, an Overrepresentation Analysis (ORA) was conducted using

the MetaboAnalystR R package (version 6.0) [26].

Machine learning(ML) modelling

Before running the ML models, the feature selection was performed using Least

Absolute Shrinkage and Selection Operator (LASSO) regression. The dataset with selected

features was divided into a training set (70%) on which the models were developed and a

testing set (30%) used to validate the trained models from the unseen data. We used various

ML models, including *Lasso, Random Forest, Naive Bayes, Partial Least Squares*, and

XGBoost, with the aim of classifying AD from HC. These models were trained and evaluated

using repeated k-fold cross-validation (5-fold and 20-repeats) to ensure robust performance

estimation. We compared the performance of models using ROC curves, confidence

intervals, and other metrics, such sensitivity, specificity, F1 score, precision, recall. For the

best models, the variable importance analysis was performed to identify the key features that

determine the classifications.

In addition, we examined the influence of *APOE* genotype on model performance and

investigated how the number of biomarkers included in the models affected their predictive

power. We incorporated the specific odds ratios (OR) for *APOE* genotypes into our model by

assigning each genotype to its corresponding risk score. These values reflect the increased

probability of developing AD for each genotype compared to the most common genotype

(baseline) of ε3/ε3, as reported in the literature [27,28]. A score of 1 was assigned to the baseline

genotype ε3/ε3, which served as a reference point.

Results

Demographic and Clinical Characteristics

A total of **107 participants**, from ADDIA cohort, were included in the study comprising

55 AD patients and **52 HC**. The mean age of AD patients observed was **75 ± 7.9 years**,

which was significantly lower than that of HC (**78 ± 4.3 years**, *p = 0.005*). The median age

was 76 years for AD and 78 years for HC, with interquartile ranges (Q1–Q3) of 71–82 years

in AD and 76–80 years in HC. The age distribution of participants ranged from 55 to 86 years

in AD and 64 to 87 years in HC, showing an overall older population consistent with

late-onset AD cases (**Table 1**).

Table 1. Demographical characteristics of participants.

Variable	AD (n=55)	HC (n=52)	Total (n=107)	t/x^2, p-value
Age				
Mean ± SD	75 ± 7.9	78 ± 4.3	76 ± 6.6	-2.824, 0.005
Median	76	78	78	
Q1 - Q3	71 - 82	76 - 80	73 - 81	
min - max	55 - 86	64 - 87	55 - 87	
Sex (n)				
Female	30 (55%)	29 (56%)	59 (55%)	0.016, 0.899
Male	25 (45%)	23 (44%)	48 (45%)	
APO-E				
e3/e4	29 (53%)	4 (8%)	33 (31%)	48.94, <0.001
e4/e4	12 (22%)	1 (2%)	13 (12%)	
e2/e4	1 (2%)	0 (0%)	1 (1%)	
e3/e3	12 (22%)	39 (75%)	51 (48%)	
e2/e3	1 (2%)	8 (15%)	9 (8%)	

Abbreviations: AD: Alzheimer's disease; HC: Healthy controls; SD: Standard deviation; APO-E:

Apolipoprotein E genotypes. p-value was calculated based on Welch's two-sample t-test or Pearson's

chi-squared test.

The sex distribution was comparable between groups, with 30 females (55%) and 25

males (45%) in the AD group, and 29 females (56%) and 23 males (44%) in the HC group (p

$= 0.899$), indicating no significant sex differences in our cohort (**Table 1**).

APOE genotyping results

APOE genotype distribution showed a **significant difference between AD and HC**

groups ($p < 0.001$). The ***APOE* ε3/ε4 genotype** was the most prevalent in AD patients (**53%**

vs. 8% in HC), whereas the **ε4/ε4 genotype**, associated with the highest risk for AD, was

present in **22% of AD patients compared to only 2% in HC**. Conversely, the ε3/ε3

genotype, commonly considered a lower-risk variant, was predominant in the HC group

(**75% vs. 22% in AD**). The **ε2/ε4 genotype was found only in 2% of AD patients**, while

the **ε2/ε3 genotype, associated with a potentially protective effect, was more frequent in**

HC (15%) than AD (2%) (**Table 1**). There is no **ε2/ε2 genotype** observed in either group in

this study **(Supplemental Figure 2(C))**.

Multivariate analysis for effect of batch, age and sex

Analysis of the impact of age on metabolite concentrations revealed a moderate number

of metabolites affected by age according to the p-value distribution **(Supplemental Figure**

3). However, after applying corrections of multiple testing, the q-value distribution showed

that only a few of these metabolites remained statistically significant, resulting in a modest

age effect. A separate analysis for sex showed also a group of metabolites that might be

affected by sex, as indicated by the p-value distribution **(Supplemental Figure 3)**. The

q-value distribution showed that only a few of these effects were significant after FDR

correction, indicating some influence of sex on tested metabolite levels. The analysis of the

interaction between sex and age demonstrated that a small number of metabolites exhibited

significant interactions. Contrary to age and sex, large proportion of metabolites exhibited

low p-values (<0.05), with the q-value distribution indicating a notable number of

metabolites affected by batch effects after correction for multiple testing **(Supplemental**

Figure 3).

PCA results after adjusting for batch, age, and sex

The first two principal components (PC1 and PC2) explained 21.09% and 8.04% of the

total variance, respectively **(<u>Figure 4. (A)</u>)**. The distribution of data points in the PCA plot

showed an overlap between the two groups. The degree of separation was not evident and not

enough to indicate the underlying metabolic variation between groups. We observed that

metabolic profiles associated with AD were not fully captured by linear dimensionality

reduction alone. The variance explained by individual principal components is shown in

<u>Figure 4. (B).</u> The cumulative variance explained by the first four principal components

reached 39.11%, showing the spread of metabolic variability across multiple dimensions. No

outliers were observed.

Figure 4. PCA of metabolomics data after adjusting for batch effects, age, and sex. (A) **PCA score plot** displays the first two principal components

(PC1 and PC2) of the metabolomics dataset, with PC1 and PC2. Each point represents an individual sample, color-coded by group: AD (green) and HC

(red). Prior to PCA, batch effects, age, and sex were regressed out to minimize potential confounding influences. (B) **The plot of explained variance by**

PC showing the percentage of variance explained by the first four principal components.

     Targeted metabolomics results

The metabolomic analysis identified **22 metabolites** with **nominal differences ($p <$**

0.05) of which 18 metabolites with AUC > 0.60, between AD and HC after adjusting for

age and sex (**Table 2**). These metabolites spanned several biochemical categories, including

acylcarnitines, phosphatidylcholines, sphingomyelins, triglycerides, and **amino acids**

(**Figure 4**). Notably, *Thr* **(AUC = 0.724), PC(30:3) (AUC = 0.763), TG(55:8) (AUC =**

0.746), and LPC(24:0) (AUC = 0.746) demonstrated higher discriminatory potential. In the

volcano plot, three metabolites **(Thr, symmetric dimethylarginine (SDMA) and**

TG(55:8)) were significantly upregulated ($p < 0.05$, LFC > 1.5), while two metabolites

(PC-O(38:3) and PC-(36:1)) were significantly downregulated ($p < 0.05$, LFC < 1.5)

(Supplemental Figure 5). The remaining metabolites did not show statistically significant

changes**.**

Table 2. ROC analysis for individual metabolites distinguishing AD from HC after adjusting for age and sex (p< 0.05; AUC>60).

Metabolite	AUC	HC_Mean(μM)	HC_SD	AD_Mean(μM)	AD_SD	pvalues	statistic	foldchange	qvalues
PC(30:3)	0.763	0.612	3.449	0.135	0.992	0.018	-2.438	-0.224	0.698
LPC(24:0)	0.746	0.040	0.009	0.043	0.021	0.031	2.194	1.181	0.698
TG(55:8)	0.737	0.385	0.659	0.232	0.502	0.007	-2.736	0.332	0.698
Thr	0.724	192.786	279.522	156.275	116.296	0.025	-2.288	0.571	0.698
SM(40:4)	0.711	0.040	0.006	0.041	0.005	0.004	2.988	1.080	0.698
PC(42:4)	0.711	0.263	0.046	0.276	0.042	0.013	2.530	1.084	0.698
AC(5:1-DC)	0.704	0.011	0.004	0.016	0.020	0.031	2.208	1.588	0.698
SDMA	0.637	0.917	1.044	0.714	0.436	0.023	-2.325	0.636	0.698
PC(29:0)	0.637	6.396	2.508	2.121	1.661	0.031	-2.195	0.805	0.698
AC(4:0-OH)	0.630	0.060	0.037	0.043	0.018	0.006	-2.842	0.728	0.698
SM(43:2)	0.629	6.745	2.859	7.512	2.443	0.032	-2.178	0.854	0.698
AC(3:0)	0.626	0.392	0.156	0.250	0.142	0.023	-2.305	0.812	0.698
AC(12:0)	0.625	0.125	0.065	0.073	0.057	0.040	-2.076	0.779	0.709
SM(39:1)	0.623	11.060	3.691	10.571	3.598	0.034	-2.146	0.869	0.698
SM(41:1)	0.619	23.311	7.386	22.438	6.380	0.033	-2.160	0.881	0.698
AC(10:3)	0.608	0.015	0.005	0.017	0.006	0.031	2.184	1.158	0.698
PC(41:3)	0.606	0.911	0.616	0.681	0.585	0.032	-2.173	0.726	0.698
PC(39:6)	0.605	2.749	1.375	1.704	0.879	0.030	-2.203	0.799	0.698

The table above presents the AUC values, mean and standard deviation (SD) of metabolites concentrations in HC and AD groups, along with statistical significance (p-values) and

fold change. Metabolites with AUC > 0.6 and p-value < 0.05 were selected. AUC values were computed using the ROCR package in R which ensured a good performance

estimation. Statistical comparisons were performed using a *two-tailed Student's t-test*, and *multiple testing corrections* were applied using the q-value method (**FDR adjusted**

P-value).

Correlations between significant metabolites and their classes

Positive and negative correlations between metabolites were identified and clusters of

correlated metabolites were observed **(Figure 7 (A))**. **LPC(24:0)** exhibited a strong positive

correlation with **SM(40:4)**, while negative correlation between **PC(29:0)** and **AC(4:0-OH)**

was observed. Analysis of significant metabolites revealed a heterogeneous distribution

across different metabolite classes **(Figure 7 (B))**. **Phosphatidylcholines** and

Acylcarnitines were the most abundant classes, each containing five distinct metabolites (n

= 5). **Sphingomyelines** were also well-represented, with four identified metabolites (n = 4).

Triglycerides, Lysophosphatidylcholines, Biogenic amines, and Amino acids were each

represented by a single metabolite (n = 1). The metabolites of the same class showed a

tendency to correlate and cluster togethers **(Figure 7 (A))**.

Figure 7: (A) **Correlation matrix of significant metabolites distinguishing AD from HC after adjusting age and sex effects.** The heatmap displays

Pearson correlation coefficients between selected metabolites (**AUC > 0.60, p-value < 0.05**). Blue indicates positive correlations, while red represents

negative correlations. Clusters of highly correlated metabolites are outlined in blue, indicating potential metabolic pathways linked to AD. (B)

Distribution of significant metabolites by class. *Acylcarnitines* (n = 5) and *Phosphatidylcholines* (n = 5) were the most represented metabolite classes,

followed by *Sphingomyelines* (n = 4). The presence of *Triglycerides, Lysophosphatidylcholines*, and *Biogenic amines* (n = 1 each).

Enrichment analysis results

The results of the ORA from MSEA are presented in **Supplemental Table 4**. This analysis

identified metabolite sets that show enrichment based on biological pathway analysis of reported

blood metabolites.

A total of six metabolite sets were found to be enriched, each associated with different

biological pathways **(Figure 8)**. The **Phosphatidylcholine Biosynthesis** pathway included one

identified metabolite, **Phosphorylcholine (PC(29:0))**, among a total of 14 metabolites in the set.

Similarly, the **Threonine and 2-Oxobutanoate Degradation** pathway contained one identified

metabolite, **L-Threonine (*Thr*)**, among 20 possible metabolites in the set.

The **Oxidation of Branched Chain Fatty Acids**, **Phospholipid Biosynthesis**, **Sphingolipid**

Metabolism, and **Glycine and Serine Metabolism** pathways were also enriched, each containing

one identified metabolite. The **Sphingolipid Metabolism** pathway had the highest number of

metabolites in the set (40), while **Glycine and Serine Metabolism** contained 59 metabolites.

Despite the differences in pathway size, each set contained only one significant hit identified in our

analysis.

Raw p-values for all enriched pathways ranged between **0.0414 and 0.167**, but after multiple

testing correction using Holm adjustment and FDR control, no pathway remained statistically

significant. However, the presence of biologically relevant metabolites in these pathways

demonstrates a potential role in disease-related metabolic alterations.

The identified metabolites in blood (serum) were mapped to their respective pathways,

alongside the full list of detectable metabolites within each pathway **(Supplemental Table 4)**.

These results provide insights into metabolic dysregulation in the studied condition and highlight

key biochemical processes that may be involved.

Figure 8. Enrichment analysis of differentially expressed metabolites in AD vs HC. Over-representation analysis of the enriched

metabolite sets, ranked by enrichment ratio. The x-axis represents the enrichment ratio, and the y-axis lists the corresponding metabolite sets.

ML model performance

Supplemental Table 7 presents the performance metrics of various ML models

evaluated on the training set using 5-fold, 20-repeat cross-validation. Two feature sets were

analyzed: 1) **57 metabolites** selected using LASSO feature selection; 2) **Top 5**

metabolites ranked by LASSO importance, evaluated with and without the inclusion of

APOE.

ML trained models demonstrated **robust performance** in classifying AD versus HC,

with **AUC values ranging from 0.823 (lowest bound) to 0.898 (highest bound)** through

a repeated cross-validation approach across different models on the 57 metabolites selected

by lasso-based feature engineering **(Supplemental Table 7)**. The **LASSO and PLS**

methods achieved the highest median AUC, 0.879 and 0.877 respectively (Figure 9;

Supplemental Table 7). However, **Random Forest** achieved an AUC of 0.863, while

Naïve Bayes and **XGBoost** displayed **slightly lower performance**, with AUC values of

0.846 and 0.842, respectively.

ROC Curves

Comparative Performance of ML Models in Classifying AD and HC

The trained models were evaluated using repeated cross-validation (5-fold, 20 repeats)

<u>Figure 9</u>. ROC Curves for ML models in classifying AD and HC. The ROC curves

depict the comparative performances of five machine learning models: LASSO (red),

Partial Least Squares (PLS, yellow), Random Forest (green), Naïve Bayes (blue), and

XGBoost (purple), in distinguishing AD from HC based on metabolomic data.

Feature importance for the best model

We employed the best model, LASSO, to identify robust biomarkers based on

metabolic profiles for discriminating between AD patients and HC. We identified 25

metabolites markers, ranking among the top markers with feature importance score

(Figure　10).　The　metabolites　include　various　**phosphatidylcholines**　(PC),

sphingomyelins　(SM),　**triglycerides**　(TG),　**lysophosphatidylcholines**　(LPC),

acylcarnitines (AC), and **amino acids** (*Thr* and *Asp*). We observed that the model

assigned high feature importance score to *Thr*. The **first 5 metabolites** were used for final

model construction, achieving an AUC of 0.816 in the train set and AUC of 0.7273 in the

test set **(Supplemental Table 7; Supplemental Table 8)**.

Figure 10. Top 25 most important metabolites identified by LASSO regression. The

importance score represents the relative contribution of each metabolite in distinguishing

between study groups based on LASSO model coefficients. Higher scores indicate greater

relevance for classification.

Impact of APOE genotyping on classification performance and validation on test set

ROC analysis further revealed the impact of ***APOE* genotype inclusion** in the models.

The trained and constructed model of the top 5 metabolites incorporating *APOE*

genotype improved classification performance, increasing the AUC from 0.834 to

0.902 (Figure 10). The **confidence interval bands** indicated reduced variability in

predictions when *APOE* was included, reinforcing its **predictive value**. The overall

sensitivity values of the trained models ranged from **0.7059 to 0.8235**, with **LASSO and**

PLS displaying superior classification ability, while specificity values ranged from

0.375 to 0.875, with **PLS achieving the highest median specificity (0.875,**

Supplemental Table 8) and the highest accuracy (0.8182, Supplemental Table 8).

In test set validation, models incorporating *APOE* **achieved an AUC of 0.7576 (95%**

CI: 0.5774, 0.8891) compared to **0.7273 (95% CI: 0.5448, 0.867) without** *APOE*,

demonstrating the **synergy between genetic and metabolic biomarkers** in improving

disease classification **(Supplemental Table 8)**.

<u>**Figure 11**</u>**. Comparison of LASSO model performance in distinguishing AD from**

HC with and without *APOE* genotyping as a feature. (A) ROC curve of the model

trained without *APOE*. B) Corresponding confusion matrix for the model without *APOE*.

(C) ROC curve of the model trained with *APOE*. (D) Corresponding confusion matrix for

the model with *APOE*.

ROC curve analysis on the constructed model yielded an AUC of 0.834 (**Figure 10**

(A)). The corresponding confusion matrix (**Figure 10 (B)**) showed that the model correctly

classified 10 AD cases and 14 HC, while 2 HC were misclassified as AD, and 6 AD cases

were misclassified as HC.

When *APOE* genotyping was included as a feature, the model exhibited improved

performance, with an AUC of 0.902 **(Figure 10 (C))**. The confusion matrix **(Figure 10**

(D)) revealed that 13 AD cases and 12 HC cases were correctly classified, whereas 4 HC

cases were misclassified as AD, and 4 AD cases were misclassified as HC.

Discussion

Recent advances in biomarker and imaging research have streamlined AD diagnosis.

Blood-based biomarkers identified in laboratory tests and brain scans are now being used

for the diagnosis of AD. Despite these advances, AD remains challenging to diagnose in its

earliest stages. The insidious onset and variable presentation of symptoms, along with

factors such as time constraints in primary care settings and the tendency to dismiss early

symptoms as normal aging, can delay diagnosis. Our study gives prominence to the

complex interaction between metabolic alterations and AD, reinforcing the relevance of

targeted metabolomics and ML in biomarker discovery.

The demographic analysis of our cohort revealed significant age differences between

AD patients and HC, with the AD group exhibiting a slightly younger mean age compared

to HC **(Table 1; Supplemental Figure 2)**. Although statistically significant, this

difference may be influenced by the fact that AD patients tended to be diagnosed slightly

earlier due to disease-related cognitive decline prompting clinical evaluation. Importantly,

no significant sex-based differences were observed **(Table 1)**, ensuring that sex did not

confound the observed metabolomic differences. These results provide a well-matched

control population for evaluating metabolic perturbations in AD while minimizing

potential biases related to sex distribution.

The strong association of *APOE*-ε4 with AD risk has been clearly documented in the

literature. Recent studies suggest that e4/e4 homozygous patients represent a novel genetic

form of AD, accounting for about 15-20% of the AD population. Authors have

demonstrated that individuals with the e4/e4 genotype will develop AD pathology with a

penetrance of 60% by the age of 60, but the condition would develop in all patients if they

live long enough [6]. In our study, the *APOE* ε3/ε4 genotype was significantly

overrepresented in AD patients, while the high-risk ε4/ε4 genotype was present in 22% of

AD patients but only 2% in HC ($p < 0.001$) **(Table 1)**. As expected, the *APOE* ε3/ε3

genotype, generally not associated with a risk of AD, was far more prevalent in HC. These

findings reinforce the well-established role of *APOE*-ε4 as a critical genetic risk factor for

late-onset AD and highlight the importance of considering *APOE* genotype in metabolic

biomarker studies.

A critical aspect of our study was evaluating potential confounding factors affecting

metabolite concentrations. While age and sex exhibited minor effects on specific

metabolites, these effects were largely reduced after multiple testing corrections,

suggesting a relatively modest impact **(Supplemental Figure 3)**. However, batch effects

were more pronounced, with a substantial number of metabolites exhibiting low p-values

even after FDR correction. This emphasizes the necessity of rigorous batch effect

correction to ensure that observed metabolic differences legitimately reflect

disease-specific alterations rather than technical variability.

Despite batch, age, and sex correction, slight differential separation between AD and

HC groups was observed in the PCA score plot **(Figure 4)**. This suggests that

AD-associated metabolic alterations are likely distributed across multiple dimensions and

may not be fully captured by linear dimensionality reduction methods. These findings

emphasize the complexity of AD metabolomic signatures, encouraging the use of

advanced machine learning and statistical modeling to extract meaningful disease-related

patterns.

Threonine (*Thr*) was significantly decreased in AD patients compared to HC (**Table

2**), a finding consistent with previous study comparing plasma free amino acid

concentrations between mild cognitive impairment (MCI) patients who remained stable

and those who converted to AD found that *Thr* levels were slightly lower in the

AD-convert group, although the difference was not statistically significant [29]. While these

findings suggest important associations between *Thr*-related markers and AD, further

research is needed to fully clarify the role of *Thr* in AD pathology and its potential as a

diagnostic or prognostic marker. *Thr* is an essential amino acid and has in fact emerged as

an important metabolite with potential relevance to AD and cognitive function. While *Thr*

itself is not directly linked to AD as a biomarker, its metabolic products and interactions

with other molecules show promise in this area. *Thr* plays a role in the synthesis of glycine,

an important neurotransmitter in the brain [30]. The metabolism of *Thr* can produce glycine,

acetyl CoA, and pyruvate, involving key enzymes such as threonine dehydrogenase (TDH)

and threonine dehydratase (STDH). This connection to glycine synthesis is significant

because glycine is involved in neurotransmission and can affect cognitive function [31].

The dysregulation of lipid species, including phosphatidylcholines (PCs),

lysophosphatidylcholines (LPCs), triglycerides (TGs), and sphingomyelins (SMs), was an

outstanding feature of our metabolomics findings (**Supplemental Figure 6**). In particular,

PC(30:3), TG(55:8), and LPC(24:0) demonstrated significant differences between AD and

HC groups (**Table 2**), supporting previous research linking lipid metabolism disturbances

to AD pathophysiology with clinical evidences [32]. Lipidomic studies have consistently

shown alterations in various lipid classes in the early stages of AD. These changes in lipid

metabolism are not limited to a single lipid class but involve multiple types of lipids [33,34].

Some PCs have been found to be significantly up-regulated in AD patients, while others

are down-regulated [34]. This shows a complex alteration in PC metabolism in AD.

Phospholipids are essential for maintaining neuronal membrane integrity, and their

dysregulation is associated with altered membrane fluidity, synaptic dysfunction, and

neuroinflammation in AD. These lipid alterations are not isolated changes but are part of a

broader dysregulation of lipid metabolism in AD. This dysregulation interacts with key AD

pathogenic mechanisms, including amyloidogenesis, bioenergetic deficits, oxidative

stress, neuroinflammation, and myelin degeneration [34]. Sphingomyelins, including

SM(40:4) and SM(43:2), showed significant differences between AD and HC, and more

up-regulated in AD with p-values of 0.004 and 0.032 respectively **(Table 2)**, which

underlined their potential relevance in AD pathology. Sphingomyelins are critical for

myelin sheath integrity and neuronal function, and their dysregulation has been linked to

amyloid β (Aβ) aggregation and tau hyperphosphorylation [35]. Similarly, altered levels of

acylcarnitines (ACs), such as AC(5:1-DC) and AC(4:0-OH), suggest disruptions in

mitochondrial function and energy metabolism, both of which are central to AD

pathogenesis [36].

The enrichment analysis provided further biological context for the identified

metabolic alterations **(Figure 8)**. Although pathway enrichment did not remain statistically

significant after multiple testing correction, the involvement of biologically relevant

pathways, such as phosphatidylcholine biosynthesis, sphingolipid metabolism, and glycine

and serine metabolism, supports potential mechanistic links to AD **(Supplemental Table**

4). Phosphatidylcholine is a critical component of cellular membranes, particularly in

neurons, and it is essential for maintaining neuronal membrane structure and function. The

disruption of phosphatidylcholine metabolism can affect synaptic transmission and

neuronal plasticity. It also has been implicated in modulating amyloid $\beta_{1\text{-}42}$ (Aβ)

aggregation and toxicity [37]. Although the specific degradation pathways of **threonine and**

2-oxobutanoate are not directly addressed in the current body of literature, the broader

context suggests that alterations in amino acid metabolism and related pathways, such as

alterations in glycolysis were observed in AD, including changes in enzyme activity and

post-translational modifications which contributes to AD pathogenesis [38]. *Tau* protein

phosphorylated at threonine 231 (*p-tau*(231)) in CSF has been correlated with cognitive

decline and conversion from mild cognitive impairment (MCI) to AD [39]. This suggests that

threonine phosphorylation, rather than degradation, may play a role in AD progression.

Our findings add to the growing body of evidence supporting metabolic disturbances in

AD and highlight the potential role of amino acid metabolism in disease development. The

pathways identified through the enrichment analysis are critical for neuronal function,

membrane integrity, and energy metabolism, all of which are disrupted in

neurodegenerative diseases.

Despite the fact that the analysis was performed on serum samples, metabolites

identified in enriched pathways were cross-referenced with previously reported findings in

CSF studies. This comparison confirmed that key metabolites such as **Choline,**

Glycerophosphocholine, and Dopamine (Supplemental Table 5), previously associated

with AD in CSF, were also detected in serum, reinforcing their relevance as potential

biomarkers. Choline, which is essentially involved in various biological processes,

including neurotransmitter synthesis and membrane formation. Its presence in both serum

and CSF supports its potential role in AD pathology [40]. Glycerophosphocholine, as a

precursor to acetylcholine, a neurotransmitter crucial for memory and cognitive function.

The detection of glycerophosphocholine in both serum and CSF underscores its

significance in AD research [40]. Dopamine, a neurotransmitter which plays an active role in

cognitive function, and its identification in both serum and CSF samples reinforces its

potential as an AD biomarker [41]. The consistency between serum and CSF findings for

these metabolites strengthens their potential as biomarkers for AD. This alignment

suggests that serum metabolomics could provide a less invasive alternative to CSF analysis

for AD diagnosis and monitoring. Besides, the identification of these metabolites in serum

samples aligns with the growing body of evidence supporting blood-based biomarkers for

AD. Recent studies have demonstrated the efficacy of serum metabolomics in

distinguishing AD patients from HCs, with some models achieving high sensitivity and

specificity [41,42]. The detection of these CSF-correlated metabolites in serum also supports

the concept of a blood-brain barrier disruption in AD, allowing for the exchange of these

molecules between the central nervous system and the peripheral circulation [40]. This

cross-validation approach not only reinforces the relevance of these metabolites as

potential AD biomarkers but also highlights the promise of serum-based metabolomics as a

powerful tool for early AD detection and monitoring of disease progression [43,44].

Among the tested models, LASSO and PLS appeared the most effective classifiers,

with the accuracy of 0.7273 and 0.8182 respectively, presenting these ML approaches to

efficiently capture relevant metabolic patterns **(Supplemental Table 8)**. Feature selection

using LASSO identified 57 key metabolite, in particular PCs, SMs, TGs, LPCs, ACs, and

amino acids (*Thr* and *Asp*) shows widespread disruptions in lipid metabolism, energy

homeostasis, amino acid processing and neurotransmitter pathways [45], emphasizing their

role in AD. These metabolic disturbances reflect well-documented mechanisms in AD,

including impaired membrane integrity, neuroinflammation, mitochondrial dysfunction,

and oxidative stress [45–47]. The effectiveness of LASSO in feature selection demonstrates

that it can apprehend metabolic signatures associated with AD, capable of driving to

improved biomarker panels for early detection and disease monitoring. Taking into

consideration the importance of features for AD classification across different models, the

features with strong predictive power for disease were delivered as candidate biomarkers

for further best model (LASSO). *Thr*, which emerged as a highly important metabolite for

best model **(Figure 10; Supplemental Table 6)**, has been linked to neurotransmitter

synthesis and cognitive function, putting in evidence its potential relevance as a biomarker

for AD.

The robust classification performance of ML models, manifestly with the 5 top

metabolites for both LASSO and PLS, calls attention to the potential of even reduced

metabolomic number of signatures in effectively distinguishing AD from elder HC

(Supplemental Table 7; Supplemental Table 8). Studies have already shown that

LASSO and PLS are in fact powerful tools for metabolomic data analysis in AD [47,48].

These methods are particularly useful for handling high-dimensional data and selecting the

most relevant features.

The inclusion of *APOE* genotyping markedly improved classification performance,

increasing AUC from 0.834 to 0.902 **(Figure 10)**, reinforcing its role as a crucial genetic

risk factor that, when combined with metabolomic data, enhances predictive power and

classification power. This improvement was accompanied by reduced variability in model

predictions **(Supplemental Table 8)**. Sensitivity ranged from 0.7059 to 0.8235, with

LASSO and PLS performing best and PLS achieving the highest median specificity **(0.875,**

Supplemental Table 8). This finding supports the interplay between genetic

predisposition and metabolic dysregulation in AD pathophysiology.

Validation on the test set confirmed the benefit of *APOE* inclusion, with AUC

increasing from 0.7273 to 0.7576 **(Supplemental Table 8)**. While *APOE* genotyping

improved model performance, it also introduced misclassification: false positives (HC

misclassified as AD) increased from 2 to 4, while false negatives (AD misclassified as HC)

decreased from 6 to 4 **(Figure 10)**. This suggests that *APOE* could enhance sensitivity but

reduce specificity, potentially overestimating AD cases. This marks the importance of

integrating genetic and metabolic biomarkers while carefully considering their individual

and combined effects on classification performance.

Despite its strengths, our study has certain **limitations**. Firstly, the sample size

remains moderate, which underscores the need for further validation in **larger**

independent cohorts to ensure the robustness and generalizability of the findings.

Secondly, while targeted metabolomics provides precise quantification of specific

metabolites, untargeted metabolomics could help to uncover **additional AD-related**

metabolic pathways, thus broadening the scope of our analysis**.** Lastly, longitudinal

studies tracking metabolite concentration changes over time would be essential to improve

our understanding of **both disease classification and progression, enhancing the**

predictive power of biomarkers.

Future research integrating larger datasets from independent cohorts and advanced

analytical approaches will be essential to translate and validate these findings into

clinically actionable tools for complementing the accurate **AD detection** and monitoring.

Examining metabolite ratios, thresholds, or overall patterns, rather than isolated

compounds, will be considered to provide a deeper understanding of AD-related

metabolomic changes. An increased focus will be placed on feature selection strategies to

mitigate misclassification while maintaining the benefits of *APOE* **integration** to pave the

way for more precise and reliable diagnostic tools in clinical settings. In closing, though

traditional statistical methods have their merits, our study demonstrated the importance of

machine learning in dealing with the complexities of **AD diagnostics**, preparing the way

for a new era in diagnostic strategies.

Conclusion

These preliminary results emphasize the effectiveness of **metabolomic serum**

biomarkers in combination with machine learning models for the discovery of

non-invasive biomarkers to better distinguish AD from HC. This study demonstrates

distinct metabolomic profiles across AD and HC, particularly emphasizing **lipid**

metabolism, mitochondrial function, and **neurotransmitter regulation** as essential

components of neurodegenerative pathology, providing insights into potential metabolic

changes underlying AD. Our findings also highlight key **metabolic disturbances in AD**,

particularly in **lipid, sphingomyelin, and amino acid metabolism**. These alterations

provide valuable insights into AD pathophysiology, offering potential biomarkers for

early diagnosis that could ultimately improve clinical outcomes and treatment strategies.

Furthermore, integrating **genetic risk factors (*APOE*) enhances classification accuracy**,

suggesting that **multi-biomarker approaches** could greatly improve AD diagnostics and

risk stratification. This **synergy between genetic and metabolic markers** underscores the

multifactorial nature of AD, showing the advantages of combining these approaches in

enhancing diagnostic accuracy and providing a more thorough understanding of the

disease.

Acknowledgments: The realization of this project was supported and funded by CombiDiag,

HORIZON - MSCA Doctoral Networks 2021 program under grant agreement

(GA):101071485. ADDIA cohort has been established thanks to the funding by the Horizon

2020 Research and Innovation program of the European Union, under the GA: 674474

(www.addia-project-h2020.eu/). The IRCCS Centro San Giovanni di Dio Fatebenefratelli of

Brescia was partially funded by Ricerca Corrente (Italian Ministry of Health).

Author Contributions: Dany Mukesha (Conceptualization Data curation; Formal analysis;

Investigation; Methodology; Project administration, Software; Visualization, Writing -

original draft; Writing - review & editing), Maïté Sarter (Data curation; Investigation;

Methodology; Writing - review & editing), Mélitine Dubray (Investigation; Methodology;

Writing - review & editing), Floris Durand (Investigation; Methodology; Writing - review &

editing), Güngör Ilhan (Writing - review & editing), Stephanie Boutillier (Funding

acquisition; Project administration; Supervision; Validation; Writing - review & editing),

Lucas Pham-Van (Project administration; Validation; Writing - review & editing), Prof.

Frédéric Blanc (Investigation; Validation; Writing - review & editing), Prof. Hakan Gürvit

(Investigation; Validation; Writing - review & editing), Prof. Tamer Demiralp (Investigation;

Validation; Writing - review & editing), Prof. Bruno Dubois (Investigation; Validation;

Writing - review & editing), Prof. Audrey Gabelle8, Moira Marizzoni (Investigation;

Validation; Writing - review & editing), Prof. Giovanni B. Frisoni (Investigation; Validation;

Writing - review & editing), Prof. Florence Pasquier (Investigation; Validation; Writing -

review & editing), Prof. François Sellal (Investigation; Validation; Writing - review &

editing), Prof. Adrian Ivanoiu (Investigation; Validation; Writing - review & editing), Prof.

Jean-Christophe Bier (Investigation; Validation; Writing - review & editing), Prof. Renaud

David (Investigation; Validation; Writing - review & editing), Prof. Jean-François Démonet

(Investigation; Validation; Writing - review & editing), Prof. Eloi Magnin (Investigation;

Validation; Writing - review & editing), Prof. Guillaume Sacco (Investigation; Project

administration; Supervision; Writing - review & editing), Prof. Hüseyin Firat (Funding

acquisition; Investigation; Project administration; Supervision; Writing - review & editing).

Statements and Declarations

Ethical considerations: There were no experiments involving animal subjects in this study.

The procedures involving experiments on human subjects were done in accord with the

ethical standards of the Committee on Human Experimentation of the institution in which the

experiments were done or in accord with the Helsinki Declaration of 1975.

Consent to participate: Not applicable

Consent for publication: No data from an individual person (including individual details,

images or videos) were used in this article. Not applicable.

Conflicts of interest: All the authors declare no conflict of interest to report with respect to

the research, authorship, and/or publication of this article.

Funding statement: All financial and material support for this research has already been

disclosed in the acknowledgements section of the manuscript.

Data availability: The data supporting the findings of this study are available on request

from the corresponding author. The data are not publicly available due to privacy or ethical

restrictions.

Supplemental Materials/ Appendix A

Supplemental Material. In the separate attached document.

References

1.　Kumar A, Sidhu J, Goyal A, et al. Alzheimer Disease. In: *StatPearls*. Treasure Island (FL):

StatPearls Publishing, http://www.ncbi.nlm.nih.gov/books/NBK499922/ (2024, accessed 26

April 2024).

2.   Davis M, O'Connell T, Johnson S, et al. Estimating Alzheimer's Disease Progression Rates

from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia.

Current Alzheimer research 2018; 15: 777.

3.   Duara R, Barker W. Heterogeneity in Alzheimer's Disease Diagnosis and Progression Rates:

Implications for Therapeutic Trials. *Neurotherapeutics* 2022; 19: 8.

4.   Anoop A, Singh PK, Jacob RS, et al. CSF Biomarkers for Alzheimer's Disease Diagnosis.

International Journal of Alzheimer's Disease 2010; 2010: 606802.

5.   Villa C, Lavitrano M, Salvatore E, et al. Molecular and Imaging Biomarkers in Alzheimer's

Disease: A Focus on Recent Insights. *Journal of Personalized Medicine* 2020; 10: 61.

6.   Fortea J, Pegueroles J, Alcolea D, et al. APOE4 homozygosity represents a distinct genetic

form of Alzheimer's disease. *Nat Med* 2024; 30: 1284–1291.

7.   Oliver SG, Winson MK, Kell DB, et al. Systematic functional analysis of the yeast genome.

Trends in Biotechnology 1998; 16: 373–378.

8.   Trushina E, Dutta T, Persson X-MT, et al. Identification of Altered Metabolic Pathways in

Plasma and CSF in Mild Cognitive Impairment and Alzheimer's Disease Using

Metabolomics. *PLOS ONE* 2013; 8: e63644.

9.   Hampel H, O'Bryant SE, Molinuevo JL, et al. Blood-based biomarkers for Alzheimer's

disease: mapping the road to the clinic. *Nature reviews Neurology* 2018; 14: 639.

10.   Wilczyńska K, Waszkiewicz N. Diagnostic Utility of Selected Serum Dementia Biomarkers:

Amyloid β-40, Amyloid β-42, Tau Protein, and YKL-40: A Review. *Journal of Clinical*

Medicine 2020; 9: 3452.

11.   Gonzalez-Covarrubias V, Martínez-Martínez E, Bosque-Plata L del. The Potential of

Metabolomics in Biomedical Applications. *Metabolites* 2022; 12: 194.

12.   González-Domínguez R, García-Barrera T, Gómez-Ariza JL. Metabolomic study of lipids in

serum for biomarker discovery in Alzheimer's disease using direct infusion mass

spectrometry. *Journal of Pharmaceutical and Biomedical Analysis* 2014; 98: 321–326.

13.   Qiu S, Cai Y, Yao H, et al. Small molecule metabolites: discovery of biomarkers and

therapeutic targets. *Signal Transduction and Targeted Therapy* 2023; 8: 132.

14.   Liebal UW, Phan ANT, Sudhakar M, et al. Machine Learning Applications for Mass

Spectrometry-Based Metabolomics. *Metabolites* 2020; 10: 243.

15.   Wang M, Li R, Qi H, et al. Metabolomics and Machine Learning Identify Metabolic

Differences and Potential Biomarkers for Frequent Versus Infrequent Gout Flares. *Arthritis*

& Rheumatology 2023; 75: 2252–2264.

16.   Zhou X, Sun X, Zhao H, et al. Biomarker identification and risk assessment of cardiovascular

disease based on untargeted metabolomics and machine learning. *Sci Rep* 2024; 14: 25755.

17.   Amoneta Diagnostics. APO-Easy®: CE-IVDR Genotyping kit for the determination of two

APOE SNPs related to AD. *APO-Easy®: CE-IVDR Genotyping kit for the determination of*

two APOE SNPs related to AD., https://amoneta-diagnostics.com/products/apo-easy/ (2024,

accessed 11 December 2024).

18.   Kooperberg C, Stone CJ. Logspline Density Estimation for Censored Data. *Journal of*

Computational and Graphical Statistics 1992; 1: 301–328.

19.   Zhang S. Nearest neighbor selection for iteratively kNN imputation. *Journal of Systems and*

Software 2012; 85: 2541–2552.

20.   Azur MJ, Stuart EA, Frangakis C, et al. Multiple imputation by chained equations: what is it

and how does it work? *International Journal of Methods in Psychiatric Research* 2011; 20:

40.

21.   Buuren S van, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations

in R. *Journal of Statistical Software* 2011; 45: 1–67.

22.   Leek JT, Scharpf RB, Bravo HC, et al. Tackling the widespread and critical impact of batch

effects in high-throughput data. *Nature reviews Genetics* 2010; 11: 10.1038/nrg2825.

23.   Bradley AP. The use of the area under the ROC curve in the evaluation of machine learning

algorithms. *Pattern Recognition* 1997; 30: 1145–1159.

24.   Lobo JM, Jiménez□Valverde A, Real R. AUC: a misleading measure of the performance of

predictive distribution models. *Global Ecology and Biogeography* 2008; 17: 145–151.

25.   Sachs MC. plotROC: A Tool for Plotting ROC Curves. *Journal of statistical software* 2017;

79: 2.

26.   Pang Z, Lu Y, Zhou G, et al. MetaboAnalyst 6.0: towards a unified platform for

metabolomics data processing, analysis and interpretation. *Nucleic Acids Research* 2024; 52:

W398–W406.

27.   Deming Y, Vasiljevic E, Morrow A, et al. Neuropathology-based APOE genetic risk score

better quantifies Alzheimer's risk. *Alzheimer's & Dementia* 2023; 19: 3406–3416.

28.   Reiman EM, Arboleda-Velasquez JF, Quiroz YT, et al. Exceptionally low likelihood of

Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study.

Nat Commun 2020; 11: 667.

29.   Ikeuchi T, Kanda M, Kitamura H, et al. Decreased circulating branched-chain amino acids

are associated with development of Alzheimer's disease in elderly individuals with mild

cognitive impairment. *Front Nutr*; 9. Epub ahead of print 14 December 2022. DOI:

10.3389/fnut.2022.1040476.

30.   Boehm G, Cervantes H, Georgi G, et al. Effect of Increasing Dietary Threonine Intakes on

Amino Acid Metabolism of the Central Nervous System and Peripheral Tissues in Growing

Rats. *Pediatr Res* 1998; 44: 900–906.

31.   Dalangin R, Kim A, Campbell RE. The Role of Amino Acids in Neurotransmission and

Fluorescent Tools for Their Detection. *Int J Mol Sci* 2020; 21: 6197.

32. Yin F. Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and

therapeutic promise. *FEBS J* 2023; 290: 1420–1453.

33. Chacko L, Veeramalla MR, Valupadas C, et al. ALZHEIMER'S DISEASE: EARLY AND

SPECIFIC DIAGNOSIS BY PLASMA LIPIDOMICS APPROACH.

34. Nie Y, Chu C, Qin Q, et al. Lipid metabolism and oxidative stress in patients with

Alzheimer's disease and amnestic mild cognitive impairment. *Brain Pathol* 2023; 34:

e13202.

35. de Wit NM, Mol K, Rodríguez-Lorenzo S, et al. The Role of Sphingolipids and Specialized

Pro-Resolving Mediators in Alzheimer's Disease. *Front Immunol*; 11. Epub ahead of print 29

January 2021. DOI: 10.3389/fimmu.2020.620348.

36. Liew G, Tse B, Ho I-V, et al. Acylcarnitine Abnormalities Implicate Mitochondrial

Dysfunction in Patients With Neovascular Age-Related Macular Degeneration. *Investigative*

Ophthalmology & Visual Science 2020; 61: 32.

37. Zhaliazka K, Matveyenka M, Kurouski D. Lipids uniquely alter the secondary structure and

toxicity of amyloid beta 1–42 aggregates. *The FEBS Journal* 2023; 290: 3203–3220.

38. Zhang X, Alshakhshir N, Zhao L. Glycolytic Metabolism, Brain Resilience, and Alzheimer's

Disease. *Front Neurosci*; 15. Epub ahead of print 28 April 2021. DOI:

10.3389/fnins.2021.662242.

39. Buerger K, Teipel SJ, Zinkowski R, et al. CSF tau protein phosphorylated at threonine 231

correlates with cognitive decline in MCI subjects. *Neurology* 2002; 59: 627–629.

40. Nho K, Kueider-Paisley A, Arnold M, et al. Serum metabolites associated with brain amyloid

beta deposition, cognition and dementia progression. *Brain Commun* 2021; 3: fcab139.

41. Nielsen JE, Andreassen T, Gotfredsen CH, et al. Serum metabolic signatures for Alzheimer's

Disease reveal alterations in amino acid composition: a validation study. *Metabolomics* 2024;

20: 12.

42. Zhao Y, Villasante-Tezanos A, Miranda-Morales EG, et al. Discovery of novel metabolic

biomarkers in blood serum for diagnosis of Alzheimer's disease. *J Alzheimers Dis* 2024; 102:

237–253.

43. Di Costanzo A, Paris D, Melck D, et al. Blood biomarkers indicate that the preclinical stages

of Alzheimer's disease present overlapping molecular features. *Sci Rep* 2020; 10: 15612.

44. Oka T, Matsuzawa Y, Tsuneyoshi M, et al. Multiomics analysis to explore blood metabolite

biomarkers in an Alzheimer's Disease Neuroimaging Initiative cohort. *Sci Rep* 2024; 14:

6797.

45. Kaddurah-Daouk R, Zhu H, Sharma S, et al. Alterations in metabolic pathways and networks

in Alzheimer's disease. *Transl Psychiatry* 2013; 3: e244–e244.

46. de Leeuw FA, Peeters CFW, Kester MI, et al. Blood-based metabolic signatures in

Alzheimer's disease. *Alzheimers Dement (Amst)* 2017; 8: 196–207.

47.   Goutman SA, Boss J, Guo K, et al. Untargeted metabolomics yields insight into ALS disease

729   mechanisms. *J Neurol Neurosurg Psychiatry* 2020; 91: 1329–1338.

730   48.   Wang K, Theeke LA, Liao C, et al. Deep learning analysis of UPLC-MS/MS-based

731   metabolomics data to predict Alzheimer's disease. *Journal of the Neurological Sciences*; 453.

732   Epub ahead of print 15 October 2023. DOI: 10.1016/j.jns.2023.120812.